Methods of permeabilizing the blood brain barrier
US-12208066-B2 · Jan 28, 2025 · US
Methods of permeabilizing the blood brain barrier
US12514828B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12514828-B2 |
| Application number | US-202418984062-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 17, 2024 |
| Priority date | Feb 8, 2018 |
| Publication date | Jan 6, 2026 |
| Grant date | Jan 6, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier. The present invention relates to a method of treating a central nervous system (CNS) cancer wherein perillyl alcohol (POH) is administered to a mammal before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell). The POH and CAR-T cells can be administered by intraarterial injection. The CNS cancer can be a malignant glioma, pilocytic astrocytomas (grade I), meningiomas, metastatic brain tumors, or pituitary adenomas.
First claim
Opening claim text (preview).
The invention claimed is: 1 . A method of treating a central nervous system (CNS) cancer, the method comprising administering to a mammal perillyl alcohol (POH) before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell), wherein the POH and CAR-T cells are administered by intraarterial injection, and wherein the CNS cancer is a malignant glioma, pilocytic astrocytomas (grade I), meningiomas, metastatic brain tumors, or pituitary adenomas. 2 . The method of claim 1 , wherein the perillyl alcohol is administered at a dose ranging from about 0.050 mg/kg to about 500 mg/kg of a body weight of the mammal. 3 . The method of claim 1 , wherein the mammal is a human. 4 . The method of claim 1 , wherein the POH is administered from about 0.2 minutes to about 60 minutes before the CAR-T cell is administered. 5 . The method of claim 1 , wherein the POH is administered from about 1 minute to about 15 minutes before the CAR-T cell is administered. 6 . The method of claim 1 , wherein the POH and the CAR-T cell are administered separately. 7 . The method of claim 1 , wherein the POH and the CAR-T cell are administered concurrently. 8 . The method of claim 1 , wherein the POH and the CAR-T cell are administered together in a pharmaceutical composition. 9 . The method of claim 1 , wherein the CNS cancer is a malignant glioma. 10 . The method of claim 9 , wherein the malignant glioma is a glioblastoma, astrocytoma, or anaplastic astrocytoma. 11 . The method of claim 9 , wherein the malignant glioma is a glioblastoma. 12 . The method of claim 1 , further comprising treating the mammal with radiation. 13 . The method of claim 1 , wherein the CAR-T cell is a CD19 CAR-T cell or a Lym-1 CAR-T cell.
Assignees
Inventors
Classifications
CD19 or B4 · CPC title
Chimeric antigen receptors [CAR] · CPC title
T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title
characterised by the dose, timing or administration schedule · CPC title
Blood cells, e.g. leukemia or lymphoma · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12514828B2 cover?
- The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier. The present invention relates to a method of treating a central nervous system (CNS) cancer wherein perillyl alcohol (POH) is administered to a mammal before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell). The POH and CAR-T cells can be a…
- Who is the assignee on this patent?
- Univ Southern California
- What technology area does this patent fall under?
- Primary CPC classification A61K31/045. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 06 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).